EQS-Adhoc: Cytos Biotechnology Ltd. will be renamed Kuros Biosciences Ltd., constitutes its Board of Directors and appoints Executive Officers

EQS Group-Ad-hoc: Cytos Biotechnology AG / Key word(s): Mergers & Acquisitions Cytos Biotechnology Ltd. will be renamed Kuros Biosciences Ltd., constitutes its Board of Directors and appoints Executive Officers

2016-01-08 / 07:00 Release of an ad hoc announcement pursuant to Art. 53 KR. The issuer is solely responsible for the content of this announcement.

Cytos Biotechnology Ltd. will be renamed Kuros Biosciences Ltd., constitutes its Board of Directors and appoints Executive Officers

Schlieren (Zurich), Switzerland, January 8, 2016 - Cytos Biotechnology Ltd ("Cytos" or the "Company" - to be renamed Kuros Biosciences Ltd.), announced today that the Board of Directors has constituted itself with Dr. Christian Itin stepping down as CEO but remaining as Chairman of the Board and Mr. Dominik Ellenrieder being appointed as the Vice Chairman of the Board. Further, the newly constituted Board elected Didier Cowling as Chief Executive Officer, Dr. Alistair Irvine as Chief Business Officer, Dr. Jason Schense as Chief Technology Officer and confirmed Harry Welten as the Chief Financial Officer. All appointments are effective upon closing of the acquisition of Kuros Biosurgery Holding AG which is expected to take place within the next few weeks.

"Yesterday, Cytos has received overwhelming support by our shareholders for the acquisition of Kuros Biosurgery Ltd. With the closing of the transaction most existing members of the Board will step down and new members of the Board of Directors have been elected. I would like to thank the outgoing Board members for their continued support and welcome the new members of the board and executive management", commented Christian Itin, Chairman of Cytos. "We are pleased that Harry Welten will continue as Chief Financial Officer and are looking forward to forming Kuros Biosciences".

For further information, please contact:

Cytos Biotechnology Ltd Harry Welten, MBA Chief Financial Officer Tel: +41 44 733 46 46 harry.welten@cytos.com

About Cytos Biotechnology Ltd

Cytos is a public biopharmaceutical company located in Schlieren (Zurich), Switzerland. The Company is listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol CYTN.

Forward Looking Statements This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.

www.cytos.com

End of ad hoc announcement

+++++ Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=XGGVUXDFGF Document title: Cytos_160108

2016-01-08 News transmitted by EQS Schweiz AG. www.eqs.com - news archive: http://switzerland.eqs.com/de/News

The issuer is responsible for the contents of the release. Language: English Company: Cytos Biotechnology AG Wagistr. 25 8952 Schlieren Switzerland Phone: +41 44 733 4747 Fax: +41 44 733 4740 E-mail: info@cytos.com Internet: www.cytos.com ISIN: CH0011025217, CH0029060735 Valor: - Listed: Regulated Unofficial Market in Berlin, Munich, Stuttgart; Open Market in Frankfurt ; SIX

End of News EQS Group News Service 427737 2016-01-08

(END) Dow Jones Newswires

   January 08, 2016 01:00 ET (06:00 GMT)- - 01 00 AM EST 01-08-16